GHK-Cu Geriatric (65+) Safety: What Older Adults and Their Clinicians Need to Know

Is any GHK-Cu product FDA-approved?

No. FDA treats GHK-Cu as a nominated bulk drug substance, not an approved medicine [1]. It is not copper histidinate (Zycubo), which FDA approved on January 12, 2026 for Menkes disease in children [6].

The topical and injectable forms are regulated differently. Copper peptide serums and creams are sold as cosmetics, and cosmetics other than color additives do not need FDA approval before sale; a product claiming to treat disease or to change the structure or function of the body would legally be a drug [5]. An injectable GHK-Cu product is not a cosmetic and is not FDA-approved [5].

FDA's list of bulk substances for state-licensed pharmacies and physicians places 'GHK-Cu (except for injectable routes of administration)' in category 1, the group still under evaluation for the bulks list [1][7]. The injectable form appears instead in FDA's nominated-but-withdrawn table [4][1]. FDA has said it intends to consult its Pharmacy Compounding Advisory Committee about GHK-Cu before the end of February 2027; no vote has taken place [1]. Compounded drugs are not FDA-approved, and FDA does not review their safety, effectiveness or quality before they are marketed [8].

What do the human trials show?

Both randomized trials found for GHK-Cu tested topical creams, and both were small. In a venous stasis ulcer trial, 86 evaluable patients received a 0.4% tripeptide copper complex cream, silver sulfadiazine 1%, or an inert vehicle; the copper cream was no different from placebo on ulcer size, while silver sulfadiazine reduced it [2]. In a laser-resurfacing trial, 13 patients completed post-treatment skin care with or without GHK-Cu; computer analysis and blinded evaluators found no significant difference in redness resolution or wrinkles, while a patient questionnaire showed a significant difference in overall skin quality favoring GHK-Cu (P=.04) [3].

A 2026 systematic review retained 64 records from a search covering 2005 to 2026 and concluded that, despite four decades of preclinical work, the human literature is thin and fragmented: most randomized trials are small, use facial cosmetic creams, and microneedle delivery has not been tested in an adequately powered registered human trial [9].

Does aging change how the body handles copper?

GHK levels in human plasma, saliva and urine are reported to decline with age, and its proposers suggest it works as a complex with copper [11]. We found no study that measured how GHK-Cu is handled in older adults, or that tracked serum copper in people using a copper peptide cream or an unapproved injection.

For copper in general, the label of cupric chloride injection (a different product, an intravenous nutrition additive) says copper is mainly excreted in bile into the gastrointestinal tract, where it is not reabsorbed, and is also eliminated through the kidneys. It says excretion is decreased in cholestasis and cirrhosis, that hepatic copper accumulation has been reported at autopsy in patients on long-term parenteral nutrition with copper above recommended doses, and that normal serum copper ranges from 80 to 163 mcg/dL [10].

What FDA says about injectable GHK-Cu safety

For injectable GHK-Cu, FDA says compounded injectable drugs containing GHK-Cu may pose a risk for immunogenicity due to the potential for aggregation and peptide-related impurities, and that there are limited data in humans to inform safety-related considerations [4]. No GHK-Cu-specific toxicity symptoms or schedule for checking serum copper are established.

The randomized human trials found used topical creams, and no adverse-event rates were found in their reports [2][3]. Topical copper peptide products are sold as cosmetics, which need no FDA approval before sale [5].